Nobuyoshi Narita

Effects of indeloxazine hydrochloride on activities of daily living in cerebrovascular disease: Evaluation by accelerometer

Abstract The effect of indeloxazine hydrochloride (60 mg/day) on activities of daily living was evaluated in 12 patients with cerebrovascular disease. An accelerometer was used to monitor body acceleration in three planes over a 24-hour period before and after drug administration. A comparative group of five patients received ticlopidine hydrochloride (300 mg/day) under the same conditions. After 8 weeks of drug administration, the total level of activity over the 24-hour monitoring period was significantly higher in the indeloxazine group than in the ticlopidine group. Indeloxazine was found to improve nighttime activity as well.

Study of the pharmacokinetics of cefpirome sulphate in the elderly

Objective: To determine the appropriate method of administration of the cephem antibiotic cefpirome sulphate in elderly patients. Method: We studied cefpiromes pharmacokinetics in patients with urinary tract infections. Patients received cefpirome sulphate 0·5 g by intravenous drip infusion over 30 mins. Results: Patients with a creatinine clearance rate (Ccr) of 80 ml/min had an AUC of 96·7 μg·h/ml and a T 1/2 of 2·36 h, whereas those with Ccr of 40–80 ml/min had an AUC of 172·0 μg·h/ml and a T 1/2 of 3·45 h and those with Ccr of < 40 ml/min had an AUC of 152 μg·h/ml and a T 1/2 of 4·86 h. Conclusion: These results indicate that decreased kidney function can cause increases in the AUC and T 1/2 of cefpirome. Thus in elderly patients and perhaps also in other patients with decreased kidney function, cefpirome should be administered at an initial dose of 0·5 g.